{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-24-000030","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.276747+00:00","generated_at":"2026-05-31T10:26:26.556173+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Amneal beats Q2 estimates, raises FY guidance; FDA approves CREXONT for Parkinson's","bullets":["Q2 net revenue $702M (+17% YoY); GAAP net income $6M ($0.02 diluted EPS).","Adjusted EBITDA $162M (+11% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.","Raising full-year 2024 guidance on broad-based growth across all segments.","FDA approved CREXONT (carbidopa/levodopa) for Parkinson's disease; launch expected September 2024.","Specialty revenue +7%, Generics +14% (driven by biosimilars), AvKARE +33%."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-24-000030","json":"https://secwatch.observer/filing/0001723128-24-000030.json","markdown":"https://secwatch.observer/filing/0001723128-24-000030.md","text":"https://secwatch.observer/filing/0001723128-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000030/0001723128-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000030/amrx-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:26:26.556173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}